PRIMIDONE Drug Patent Profile

When do Primidone patents expire, and what generic alternatives are available?

Primidone is a drug marketed by Amneal Pharm, Chartwell Rx, Hikma Intl Pharms, Impax Labs, Lannett, Oxford Pharms, Pharmobedient, Rubicon Research, Tp Anda Holdings, and Watson Labs. and is included in eleven NDAs.

The generic ingredient in PRIMIDONE is primidone. There are seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the primidone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Primidone

A generic version of PRIMIDONE was approved as primidone by WATSON LABS on December 31^st, 1969.

Summary for PRIMIDONE

US Patents:	0
Applicants:	10
NDAs:	11

US Patents and Regulatory Information for PRIMIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharm	PRIMIDONE	primidone	TABLET;ORAL	040866-001	Apr 23, 2008	AB	RX	No	No
Tp Anda Holdings	PRIMIDONE	primidone	TABLET;ORAL	040626-001	Sep 29, 2005	AB	RX	No	No
Impax Labs	PRIMIDONE	primidone	TABLET;ORAL	040717-001	Feb 12, 2008		DISCN	No	No
Chartwell Rx	PRIMIDONE	primidone	TABLET;ORAL	040862-002	Oct 3, 2008		DISCN	No	No

Primidone Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Primidone, an antiepileptic drug, presents a nuanced investment landscape. Its established efficacy in treating focal seizures and generalized tonic-clonic seizures is offset by a maturing patent life and the emergence of newer therapeutic options. This analysis examines the drug's market position, patent status, regulatory environment, and competitive landscape to inform R&D and investment decisions.

What is the current market position of Primidone?

Primidone, marketed primarily under the brand name Mysoline, holds a modest but persistent share in the antiepileptic drug (AED) market. Its therapeutic utility is primarily focused on specific seizure types, positioning it as a second- or third-line treatment option for patients who have not responded adequately to first-line therapies or who experience specific seizure patterns amenable to primidone's mechanism of action.

The drug operates within the broader epilepsy market, which is characterized by a substantial patient population. In the United States, epilepsy affects an estimated 3.4 million people, with approximately 150,000 new cases diagnosed annually [1]. Globally, the prevalence of epilepsy is estimated at 50 million people [2]. This large patient base provides a foundational demand for AEDs.

Primidone's market share has been influenced by several factors:

• Established Efficacy: For its approved indications, primidone offers a well-documented therapeutic profile. It is a prodrug that is metabolized in the body to phenobarbital and phenylacetylurea (PAU), both of which have anticonvulsant properties [3]. This dual metabolite action contributes to its effectiveness.
• Generic Competition: As a long-established drug, primidone is widely available as a generic. This has significantly eroded brand-name sales and intensified price competition among manufacturers.
• Emergence of Newer AEDs: The past two decades have seen a proliferation of novel AEDs with improved tolerability profiles, expanded indications, and different mechanisms of action. Drugs like levetiracetam, lacosamide, and perampanel, among others, have captured significant market share, often displacing older medications like primidone in treatment algorithms [4]. These newer agents frequently offer better seizure control with fewer side effects or are better suited for specific patient populations.
• Side Effect Profile: Primidone's known side effects, including drowsiness, dizziness, and ataxia, can limit its use, particularly in certain patient demographics or when used as monotherapy [3]. This can drive prescribers towards alternatives with more favorable tolerability.
• Specific Niche: Despite the challenges, primidone retains a role for certain patients, especially those who have benefited from it for many years and do not experience significant adverse effects, or in cases where specific seizure types are addressed more effectively by its mechanism of action. Its place in treatment guidelines, while evolving, still acknowledges its utility.

The global antiepileptic drugs market was valued at approximately $23.7 billion in 2022 and is projected to reach $31.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.5% [5]. Within this, primidone's market contribution is a small fraction, primarily driven by generic sales and specific geographic markets where it may still be a preferred option.

What is the patent and regulatory status of Primidone?

Primidone's original patents have long expired, leading to its status as a generic drug. The drug was first approved by the U.S. Food and Drug Administration (FDA) in 1954 [6].

• Patent Expiration: As an early-generation antiepileptic, primidone's foundational patents expired decades ago. This has allowed multiple generic manufacturers to produce and market the drug without paying licensing fees to the original patent holder.
• Generic Availability: Primidone is available from numerous generic manufacturers globally. This competition drives down prices and limits the profitability potential for any single generic producer.
• Regulatory Approvals: Primidone is approved for the treatment of:
  • Focal seizures (partial seizures)
  • Generalized tonic-clonic seizures (grand mal seizures)
  • In some regions, it may be used as adjunctive therapy for other seizure types [3].
• Post-Market Surveillance: Like all approved drugs, primidone is subject to ongoing post-market surveillance by regulatory agencies. This includes monitoring for adverse events, product quality, and adherence to manufacturing standards. The FDA maintains a database of post-market drug safety information.
• Orphan Drug Status: Primidone is not designated as an orphan drug. Its indication for epilepsy covers a large patient population, not a rare disease.
• Exclusivity Periods: As a generic drug, primidone does not benefit from the market exclusivity periods (e.g., New Chemical Entity exclusivity, Orphan Drug exclusivity) that are granted to novel pharmaceuticals. Generic manufacturers typically achieve market entry after the expiration of relevant patents and data exclusivity.

The regulatory landscape for generics is well-established, focusing on demonstrating bioequivalence to the reference listed drug. This allows for rapid market entry once patent and exclusivity barriers are removed, contributing to the pricing pressures seen with primidone.

What is the competitive landscape for Primidone?

The competitive landscape for primidone is crowded and fragmented, primarily dominated by generic products. Its direct competitors are other antiepileptic drugs, both older and newer generations.

Key Competitive Factors:

• Pricing: As a generic, price is a primary competitive differentiator. Generic manufacturers compete fiercely on cost, influencing market access and prescription volume.
• Availability and Supply Chain: Consistent supply and broad distribution networks are crucial for generic drugs. Disruptions can lead to product shortages, opening opportunities for competitors.
• Prescriber Preferences and Guidelines: Clinical practice guidelines and physician experience play a significant role. While older guidelines may have featured primidone more prominently, newer guidelines often prioritize newer AEDs with better safety and efficacy profiles for specific patient groups.
• Tolerability and Side Effect Profiles: Newer AEDs often offer improved tolerability compared to older drugs like primidone. This is a major competitive advantage, as minimizing side effects is a key treatment goal.
• Mechanism of Action and Efficacy: Competitors offer a diverse range of mechanisms of action, targeting different ion channels, neurotransmitters, or synaptic pathways. This allows for tailored treatment approaches and provides alternatives when primidone is ineffective or poorly tolerated.

Major Competitors (Therapeutic Class - AEDs):

• Older Generation AEDs (also largely generic):
  • Phenytoin
  • Carbamazepine
  • Valproic Acid
  • Phenobarbital (a metabolite of primidone, often used independently)
  • Ethosuximide (primarily for absence seizures)
• Newer Generation AEDs (many with branded and generic forms):
  • Gabapentin/Pregabalin: Widely prescribed for various seizure types and neuropathic pain.
  • Lamotrigine: Broad-spectrum efficacy.
  • Levetiracetam: Very common first- or second-line agent due to its favorable tolerability and broad spectrum.
  • Topiramate: Used for focal and generalized seizures, migraine prophylaxis.
  • Oxcarbazepine: Similar to carbamazepine but with an improved tolerability profile.
  • Lacosamide: Approved for adjunctive treatment of focal-onset seizures.
  • Perampanel: Targets AMPA receptors, broad-spectrum.
  • Eslicarbazepine Acetate: Advanced generation of oxcarbazepine.
  • Brivaracetam: Similar mechanism to levetiracetam but with potentially different pharmacokinetics.

Market Dynamics:

The market is characterized by a continuous influx of new AEDs, aiming to address unmet needs, improve tolerability, or offer novel mechanisms of action. This dynamic environment puts constant pressure on older drugs like primidone. Investment in primidone is unlikely to be driven by market growth potential but rather by maintaining a cost-effective supply for existing patient demand and potential niche applications.

What are the potential R&D and investment opportunities related to Primidone?

Given primidone's established generic status and maturing market, direct R&D investment focused on new indications or novel formulations is limited. However, opportunities may exist in adjacent areas or through strategic repurposing, albeit with significant caveats.

Potential R&D Avenues:

• Pharmacokinetic/Pharmacodynamic (PK/PD) Optimization:
  • Extended-Release Formulations: Investigating novel extended-release (ER) or sustained-release (SR) formulations could potentially improve adherence by reducing dosing frequency and smoothing out plasma concentrations, thereby minimizing peak-related side effects like drowsiness. This would require significant development and regulatory hurdles for bioequivalence and potentially new patent claims on the formulation technology itself, not the active pharmaceutical ingredient (API).
  • Combination Therapies: Research into synergistic effects with newer AEDs. While challenging due to existing complex regimens, identifying specific patient subgroups where a primidone-based combination offers superior outcomes with manageable toxicity could be an area of exploration. This would likely be investigator-initiated research rather than large-scale pharmaceutical R&D.
• Repurposing for Non-Epilepsy Indications:
  • Essential Tremor: Primidone has been used off-label for essential tremor for decades. While not a primary indication, further investigation into its efficacy, optimal dosing, and comparison with current tremor treatments could solidify its role or identify specific patient profiles where it is advantageous. This would require dedicated clinical trials and regulatory approval for the new indication.
  • Other Neurological Disorders: Exploring potential benefits in other neurological conditions with underlying neuronal hyperexcitability, although this is highly speculative and would necessitate extensive preclinical and clinical investigation.
• Manufacturing Process Improvement:
  • Cost Reduction: Investing in process chemistry to improve the efficiency and reduce the cost of primidone API synthesis. This is a common strategy for generic manufacturers to maintain competitiveness.
  • Green Chemistry: Developing more environmentally sustainable manufacturing processes for primidone.

Investment Considerations:

• Generic Manufacturing: Investment can be directed towards companies that specialize in the efficient, high-quality manufacturing of generic drugs. The profitability in this space comes from operational excellence and market share capture, not from novel drug discovery.
• API Supply Chain: Securing reliable and cost-effective API sources for primidone is a critical factor for generic manufacturers. Investment in companies that control key intermediates or exhibit strong supply chain management in this area could be considered.
• Specialty Pharma Focusing on Established Drugs: Some specialty pharmaceutical companies focus on optimizing and marketing established, off-patent drugs, potentially through improved formulations or targeted marketing efforts.
• Niche Market Opportunities: Identifying specific geographic markets or patient populations where primidone remains a preferred or cost-effective option due to local formularies, pricing sensitivities, or historical prescriber comfort.

Challenges:

• Limited Growth Potential: The primary barrier to significant investment is the inherent limitation in growth potential for an established, genericized drug. The market is largely saturated.
• Regulatory Hurdles for New Indications/Formulations: Obtaining new FDA approvals for expanded indications or novel formulations requires substantial investment in clinical trials and regulatory affairs, with no guarantee of success.
• Intense Generic Competition: The price erosion from competition makes high margins difficult to achieve.

Any R&D or investment strategy must acknowledge that primidone is a mature product. Opportunities are likely to be incremental, focusing on cost efficiencies, niche applications, or formulation improvements rather than breakthrough discoveries.

Key Takeaways

• Primidone is a generic antiepileptic drug with established efficacy for focal and generalized tonic-clonic seizures.
• Its market position is that of a second- or third-line therapy, facing significant competition from newer AEDs with improved tolerability and broader indications.
• Original patents have expired, leading to widespread generic availability and intense price competition.
• Potential R&D opportunities are limited and largely focus on formulation improvements (e.g., extended-release) or exploring off-label uses like essential tremor.
• Investment is primarily directed towards generic manufacturing efficiency, supply chain management, and companies optimizing established drugs rather than novel drug discovery.

FAQs

1. What are the primary approved uses of primidone? Primidone is approved for the treatment of focal seizures (partial seizures) and generalized tonic-clonic seizures (grand mal seizures).

2. Has primidone's patent protection expired? Yes, primidone's original patents expired many decades ago, making it a widely available generic drug.

3. What are the main challenges facing primidone in the current market? Primidone faces challenges from the emergence of newer antiepileptic drugs with better tolerability profiles and broader efficacy, as well as intense price competition from other generic manufacturers.

4. Are there any significant R&D opportunities for primidone? Limited R&D opportunities exist, primarily focusing on developing novel formulations like extended-release versions or investigating its efficacy in off-label indications such as essential tremor.

5. What type of investment would be most relevant for primidone? Investment would typically be directed towards companies involved in efficient generic manufacturing, optimizing existing supply chains, or specialty pharma firms focused on managing and potentially improving established, off-patent medications.

Cited Sources

[1] Centers for Disease Control and Prevention. (2023, February 21). Epilepsy fast facts. U.S. Department of Health & Human Services. Retrieved from https://www.cdc.gov/epilepsy/data/fast-facts.html

[2] World Health Organization. (2022, February 10). Epilepsy. Retrieved from https://www.who.int/news-room/fact-sheets/detail/epilepsy

[3] U.S. Food and Drug Administration. (n.d.). Prescribing Information for Mysoline (primidone). [Note: Specific PI links change; general FDA drug information search is the source.]

[4] Perucca, E. (2015). New antiepileptic drugs: a pharmacological and clinical update. The Lancet Neurology, 14(6), 614-627. doi: 10.1016/S1474-4422(15)00018-6

[5] Grand View Research. (2023, October). Antiepileptic Drugs Market Size, Share & Trends Analysis Report By Drug Type, By Distribution Channel, By Region, And Segment Forecasts, 2023-2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/antiepileptic-drugs-market

[6] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm [Note: This is a general link to the FDA drug database; specific approval dates for older drugs are confirmed through database search.]